{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:31:51Z","timestamp":1793640711008,"version":"4.5.1"},"reference-count":22,"publisher":null,"issue":"12","license":[{"start":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T00:00:00Z","timestamp":1703548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/lib.ossn.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"abstract":"<jats:p>\n                    <jats:italic>Aim<\/jats:italic>\n                    \u00a0\u00a0\u00a0\u00a0\u00a0 A 12-month evaluation of the potentialities of the angiotensin II receptor inhibitor olmesartan (Olme) and the angiotensin receptor and neprilysin inhibitor (ARNI) sacubitril\/valsartan in patients with arterial hypertension (AH) and dyslipidemia in the dynamics of the following indicators of chronic heart failure (CHF): N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), LV global longitudinal strain (LV GLS) in diffuse myocardial fibrosis (MF) previously diagnosed by magnetic resonance imaging (MRI).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Material and methods<\/jats:italic>\n                    \u00a0 Olmesartan medoxomil (n=56) and sacubitril\/valsartan (n=63) were used for 12 months in patients with hypertension, dyslipidemia and NYHA functional class II-III CHF with mid-range LVEF (CHFmrEF). MF was diagnosed by the following MRI criteria: late gadolinium enhancement and an increased proportion of extracellular matrix (33% or more). The frequency of persisting late gadolinium enhancement and the increased proportion of extracellular matrix (33% or more) was evaluated at 12 months; changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), NT-proBNP, and LV GLS were evaluated after 3, 6, and 12 months of follow-up.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Results<\/jats:italic>\n                    Baseline parameters did not differ between groups. The late gadolinium enhancement and increased proportion of extracellular matrix were present at baseline in all patients of both groups (100%; p=1.0). Already at 3 months, statistically significant decreases in SBP and DBP were observed in both groups. In addition, the LV GLS monitoring showed LV GLS significantly increased in both groups after 3 months and continued changing after 6 and 12\u2008months. The NT-proBNP concentration significantly decreased in both groups already after 3 months and continued to decrease after 6 and 12\u2008months. At 6 and 12 months, sacubitril\/valsartan was superior to olmesartan in reducing SBP and NT-proBNP and in restoring LV GLS. At 12 months, the incidence of persisting, abnormal late gadolinium enhancement and increased proportion of extracellular matrix was significantly less in the ARNI group.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusion<\/jats:italic>\n                    \u00a0\u00a0\u00a0\u00a0\u00a0 Olmesartan was demonstrated effective in the multi-modality therapy of CHFmrEF and MF in patients with AH and dyslipidemia. ARNI was superior to olmesartan in this regard, but further research of this issue is required.\n                  <\/jats:p>\n                  <jats:p>\u00a0<\/jats:p>","DOI":"10.18087\/cardio.2023.12.n2557","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T06:11:05Z","timestamp":1703830265000},"page":"31-38","source":"Crossref","is-referenced-by-count":1,"title":["The Clinical Evolution of Diffuse Myocardial Fibrosis in Patients With Arterial Hypertension and Heart Failure With Mildly Reduced Ejection Fraction Treated by Olmesartan or Sacubitril \/ Valsartan"],"prefix":"10.68900","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2110-0970","authenticated-orcid":true,"given":"L. V.","family":"Shulzhenko","sequence":"first","affiliation":[{"name":"Ochapovsky Territorial Clinical Hospital #1, Krasnodar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. V.","family":"Pershukov","sequence":"additional","affiliation":[{"name":"Bobrov District Hospital, Bobrov of the Voronezh Region;\r\nOsh State University, Osh;\r\nKazakh-Russian Medical University, Almaty"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4251-0327","authenticated-orcid":true,"given":"T. A.","family":"Batyraliev","sequence":"additional","affiliation":[{"name":"Salymbekov University, Bishkek"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5622-3316","authenticated-orcid":true,"given":"Z. A.","family":"Karben","sequence":"additional","affiliation":[{"name":"Sanko University, Sehitkamil, Gaziantep"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5163-4747","authenticated-orcid":true,"given":"O. V.","family":"Gurovich","sequence":"additional","affiliation":[{"name":"Burdenko Voronezh State Medical University, Voronezh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4143-8899","authenticated-orcid":true,"given":"D. V.","family":"Fettser","sequence":"additional","affiliation":[{"name":"Municipal Clinical Hospital #52, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5492-7552","authenticated-orcid":true,"given":"T. N.","family":"Kuznetsova","sequence":"additional","affiliation":[{"name":"Voronezh Regional Clinical Hospital #1, Voronezh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7473-5483","authenticated-orcid":true,"given":"E. Yu.","family":"Ivanenkova","sequence":"additional","affiliation":[{"name":"Voronezh Regional Clinical Hospital #1, Voronezh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0491-5334","authenticated-orcid":true,"given":"B. A.","family":"Akbalaeva","sequence":"additional","affiliation":[{"name":"Osh State University, Osh;\r\nAliev Osh-Cardio Medical Center, Osh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8587-705X","authenticated-orcid":true,"given":"N.","family":"Rayimbek uulu","sequence":"additional","affiliation":[{"name":"Osh State University, Osh;\r\nAliev Osh-Cardio Medical Center, Osh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7451-9499","authenticated-orcid":true,"given":"S.","family":"Toygonbaev","sequence":"additional","affiliation":[{"name":"Southern Regional Research Center of Cardiovascular Surgery, Jalal-Abad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5318-0995","authenticated-orcid":true,"given":"A. T.","family":"Mansharipova","sequence":"additional","affiliation":[{"name":"Kazakh-Russian Medical University, Almaty"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5045-7813","authenticated-orcid":true,"given":"A. O.","family":"Seidalin","sequence":"additional","affiliation":[{"name":"Kazakh-Russian Medical University, Almaty"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0722-8433","authenticated-orcid":true,"given":"E. I.","family":"Zyablova","sequence":"additional","affiliation":[{"name":"Ochapovsky Territorial Clinical Hospital #1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0175-0343","authenticated-orcid":true,"given":"R. K.","family":"Kalmatov","sequence":"additional","affiliation":[{"name":"Osh State University, Osh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8307-8203","authenticated-orcid":true,"given":"Zh. B.","family":"Imetova","sequence":"additional","affiliation":[{"name":"Osh State University, Osh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7080-8665","authenticated-orcid":true,"given":"V. V.","family":"Vinogradskaia","sequence":"additional","affiliation":[{"name":"City of Health Clinic, Voronezh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9208-7446","authenticated-orcid":true,"given":"E. V.","family":"Gaydukova","sequence":"additional","affiliation":[{"name":"Burdenko Main Military Clinical Hospital, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2023,12,26]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Kade A.Kh., Polyakov P.P., Muratova A.Yu., Bogdanova Yu.A., Vcherash nyuk S.P., Turovaya A.Yu. et al. Mechanisms of myocardial fibrosis. Modern Problems of Science and Education. 2021;2:192. DOI: 10.17513\/spno.30609","DOI":"10.17513\/spno.30609"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Karamitsos TD, Arvanitaki A, Karvounis H, Neubauer S, Ferreira VM. Myocardial Tissue Characterization and Fibrosis by Imaging. JACC: Cardiovascular Imaging. 2020;13(5):1221\u201334. DOI: 10.1016\/j.jcmg.2019.06.030","DOI":"10.1016\/j.jcmg.2019.06.030"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Barton AK, Tzolos E, Bing R, Singh T, Weber W, Schwaiger M et al. Emerging molecular imaging targets and tools for myocardial fibrosis detection. European Heart Journal - Cardiovascular Imaging. 2023;24(3):261\u201375. DOI: 10.1093\/ehjci\/jeac242","DOI":"10.1093\/ehjci\/jeac242"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Lewandowski D, Yang EY, Nguyen DT, Khan MA, Malahfji M, El Tallawi C et al. Relation of Left Ventricular Diastolic Function to Global Fibrosis Burden: Implications for Heart Failure Risk Stratification. JACC: Cardiovascular Imaging. 2023;16(6):783\u201396. DOI: 10.1016\/j.jcmg.2022.12.027","DOI":"10.1016\/j.jcmg.2022.12.027"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Lurz JA, Luecke C, Lang D, Besler C, Rommel K-P, Klingel K et al. CMR\u2013Derived Extracellular Volume Fraction as a Marker for Myocardial Fibrosis. JACC: Cardiovascular Imaging. 2018;11(1):38\u201345. DOI: 10.1016\/j.jcmg.2017.01.025","DOI":"10.1016\/j.jcmg.2017.01.025"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Golukhova E.Z., Aleksandrova S.A., Berdibekov B.Sh. Predictive role of quantification of myocardial fibrosis using delayed contrast-enhanced magnetic resonance imaging in nonischemic dilated cardiomyopathies: a systematic review and meta-analysis. Russian Journal of Cardiology. 2021;26(12):189\u201397. DOI: 10.15829\/1560-4071-2021-4776","DOI":"10.15829\/1560-4071-2021-4776"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez A, Schelbert EB, D\u00edez J, Butler J. Myocardial Interstitial Fibrosis in Heart Failure. Biological and Translational Perspectives. Journal of the American College of Cardiology. 2018;71(15):1696\u2013706. DOI: 10.1016\/j.jacc.2018.02.021","DOI":"10.1016\/j.jacc.2018.02.021"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Zaitsev V.V., Gurshchenkov A.V., Mitrofanova L.B., Ryzhkov A.V., Kazakova E.E., Badaev K.D. et al. Clinical significance of different assesment methods of myocardial fibrosis in patients with hypertrophic cardiomyopathy. Kardiologiia. 2020;60(3):44\u201350. DOI: 10.18087\/cardio.2020.3.n561","DOI":"10.18087\/cardio.2020.3.n561"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Berdibekov B.Sh., Aleksandrova S.A., Golukhova E.Z. Quantitative assessment of myocardial fibrosis using delayed contrast-enhanced magnetic resonance imaging in noncoronarogenic ventricular arrhythmias. Creative Cardiology. 2021;15(3):342\u201353. DOI: 10.24022\/1997-3187-2021-15-3-342-353","DOI":"10.24022\/1997-3187-2021-15-3-342-353"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Zagrosek A, Abdel-Aty H, Boy\u00e9 P, Wassmuth R, Messroghli D, Utz W et al. Cardiac Magnetic Resonance Monitors Reversible and Irreversible Myocardial Injury in Myocarditis. JACC: Cardiovascular Imaging. 2009;2(2):131\u20138. DOI: 10.1016\/j.jcmg.2008.09.014","DOI":"10.1016\/j.jcmg.2008.09.014"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Golukhova E.Z., Alexandrova S.A., Bulaeva N.I., Mrikaev D.V., Gromova O.I., Berdibekov B.Sh. Prognostic value of myocardial strain by magnetic resonance imaging in nonischemic dilated cardiomyopathy: a systematic review and meta-analysis. Kardiologiia. 2022;62(10):35\u201341. DOI: 10.18087\/cardio.2022.10.n2034","DOI":"10.18087\/cardio.2022.10.n2034"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiological Reviews. 2007;87(4):1285\u2013342. DOI: 10.1152\/physrev.00012.2007","DOI":"10.1152\/physrev.00012.2007"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Song K, Nam Y-J, Luo X, Qi X, Tan W, Huang GN et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature. 2012;485(7400):599\u2013604. DOI: 10.1038\/nature11139","DOI":"10.1038\/nature11139"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Dimas V, Ayers C, Daniels J, Joglar JA, Hill JA, Naseem RH. Spironolactone Therapy is Associated with Reduced Ventricular Tachycardia Rate in Patients with Cardiomyopathy. Pacing and Clinical Electrophysiology. 2011;34(3):309\u201314. DOI: 10.1111\/j.1540-8159.2010.02888.x","DOI":"10.1111\/j.1540-8159.2010.02888.x"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Lee T-M, Lin M-S, Chou T-F, Chang N-C. Additive effects of combined blockade of AT 1 receptor and HMG-CoA reductase on left ventricular remodeling in infarcted rats. American Journal of Physiology-Heart and Circulatory Physiology. 2006;291(3):H1281\u20139. DOI: 10.1152\/ajpheart.00792.2005","DOI":"10.1152\/ajpheart.00792.2005"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Pi\u00f1a IL, Camacho A, Ibrahim NE, Felker GM, Butler J, Maisel AS et al. Improvement of Health Status Following Initiation of Sacubitril\/Valsartan in Heart Failure and Reduced Ejection Fraction. JACC: Heart Failure. 2021;9(1):42\u201351. DOI: 10.1016\/j.jchf.2020.09.012","DOI":"10.1016\/j.jchf.2020.09.012"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Cheung DG, Aizenberg D, Gorbunov V, Hafeez K, Chen C, Zhang J. Efficacy and safety of sacubitril\/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study. The Journal of Clinical Hypertension. 2018;20(1):150\u20138. DOI: 10.1111\/jch.13153","DOI":"10.1111\/jch.13153"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Jo S, Moon H, Park K, Sohn C-B, Kim J, Kwon Y-S et al. Design and rationale for a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial: study protocol for a randomized controlled trial. Trials. 2022;23(1):36. DOI: 10.1186\/s13063-021-05970-7","DOI":"10.1186\/s13063-021-05970-7"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Efficacy of sacubitril\/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study. Hypertension Research. 2022;45(5):824\u201333. DOI: 10.1038\/s41440-021-00819-7","DOI":"10.1038\/s41440-021-00819-7"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599\u2013726. DOI: 10.1093\/eurheartj\/ehab368","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Lee V, Zheng Q, Toh D-F, Pua CJ, Bryant JA, Lee C-H et al. Sacubitril\/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded end-point clinical trial protocol. Frontiers in Cardiovascular Medicine. 2023;10:1248468. DOI: 10.3389\/fcvm.2023.1248468","DOI":"10.3389\/fcvm.2023.1248468"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"D\u00edez J, Querejeta R, L\u00f3pez B, Gonz\u00e1lez A, Larman M, Mart\u00ednez Ubago JL. Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive Patients. Circulation. 2002;105(21):2512\u20137. DOI: 10.1161\/01.CIR.0000017264.66561.3D","DOI":"10.1161\/01.CIR.0000017264.66561.3D"}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/lib.ossn.ru\/jour\/article\/viewFile\/2557\/1478","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:16:34Z","timestamp":1793639794000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/2557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,26]]},"references-count":22,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,27]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2023.12.n2557","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,26]]}}}